Close Menu

GenMark

Overall, 10 of the 26 companies in the 360Dx Index declined last month, but it still beat the broader markets. 

Foundation Medicine, Invitae, Accelerate Diagnostics, and Myriad Genetics each saw their share prices jump more than 20 percent last month.

CEO Hany Massarany said that 2017 will be a pivotal year for the company as it expects to launch the ePlex sample-to-answer system in the US.

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco, CA, Day 3.

The firm also reported that full-year 2016 revenues grew 25 percent over 2015, driven in part by strong ePlex instrument sales.

GenMark's CEO said that the firm continues to focus on growing the ePlex instrument's global reach and expanding its menu. 

Encouraged by positive customer feedback from early installations, the firm is shifting its sales focus to the ePlex system and respiratory pathogen panel.   

The investment bank said it has heard positive feedback from early adopters in Europe of GenMark's ePlex system and respiratory panel.

The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.

Pages